Ofatumumab With Ivac for Dlbcl Patients Who Failed R-Chop and Were Not Candidates for High-Dose Therapy and Asct - Phase 2 Trial of the Polish Lymphoma Research Group (Plrg-8) - E. Paszkiewicz-Kozik, W. Michalski, M. Taszner, W. Knopińska-Posłuszny, M. Mordak-Domagała, J. Najda, A. Borawska, J. Romejko-Jarosińska, M. Chełstowska, M. Świerkowska, A. Dąbrowska-Iwanicka, A. Malenda, A. Druzd-Sitek, R. Konecki, B. Kuniega - Dissemin

Language
Login

Published in

Wiley, Hematological Oncology, (37), p. 436-437, 2019

DOI: 10.1002/hon.111_2631

Links

ORCID
Wiley

Tools

Export citation

Search in Google Scholar

Ofatumumab With Ivac for Dlbcl Patients Who Failed R-Chop and Were Not Candidates for High-Dose Therapy and Asct - Phase 2 Trial of the Polish Lymphoma Research Group (Plrg-8)

Journal article published in 2019 by E. Paszkiewicz-Kozik, W. Michalski, M. Taszner, W. Knopińska-Posłuszny, M. Mordak-Domagała, J. Najda, A. Borawska, J. Romejko-Jarosińska, M. Chełstowska, M. Świerkowska, A. Dąbrowska-Iwanicka, A. Malenda, A. Druzd-Sitek, R. Konecki, B. Kuniega and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO